GIMBHI: LifeStance Health Q1 2026 Earnings

Uncategorized
Written By

Sources: LifeStance Health 10-Q (filed May 7, 2026)

Financial Performance

  • Revenue $403.5M (21% YoY)

  • Income from operations $22.3M vs $1.6M YoY

  • Net income $14.2M vs $0.7M YoY

  • Adjusted EBITDA $51.1M (47% YoY, 12.7% margin)

  • Adj. EBITDA margin up from 10.4% YoY (operating leverage inflection)

  • Center Margin $135.9M (33.7% of revenue, up from 33.0%)

  • G&A grew only 6% while revenue grew 21% (fixed-cost leverage story)

  • SBC fell 18% YoY to $15.2M (3.8% of revenue vs 5.6%)

  • EPS $0.04 basic and diluted vs $0.00 YoY

  • $194.8M cash, $283M term loan debt, $100M revolver undrawn

Unit Economics & Engagement

  • 2.5M visits completed (18% YoY)

  • 8,349 licensed clinicians (net adds of 814 YoY, ~11% headcount growth)

  • Revenue per visit ~$161 (up modestly, ~3% rate increase)

  • Growth decomposition: ~18% volume + ~3% rate

  • Revenue per clinician ~$770K annualized

  • Contribution after center costs ~$260K per clinician per year

  • Existing clinician productivity gains suggest demand side isn’t saturated

Payor Leverage & Mix

  • Commercial 88% of revenue, Government 6%, Self-pay 5%

  • Two payors are 13% and 15% of revenue (concentration = leverage at this scale)

  • Explicit playbook: terminating low-volume payor contracts to force rate improvement

  • Rate parity between virtual and in-person secured by contract or payor policy

  • OBBBA Medicaid changes immaterial (Medicaid exposure tiny)

  • Virtual vs in-person visit mix conspicuously not disclosed

Network & Operations

  • W-2 clinician model with 8,349 providers across subsidiaries and supported practices

  • Friendly-PC structure: acquires 100% of non-medical assets, physician-owners retain equity

  • Controlled via MSA + Stock Transfer Restriction agreements (underrated multi-state moat)

  • Multi-channel CAC: payor referrals, PCP/specialist partnerships, internal referrals, online marketing

  • Material weaknesses in internal controls unresolved since 2019 (CEO/CFO certify disclosure controls “not effective”)

  • Malpractice insurance cap surprisingly low for size: $3K per claim / $8K annual aggregate

Capital Allocation & M&A

  • $100M buyback authorized Feb 2026; deployed $49.1M at $7.01 avg in Q1

  • $50.9M remaining under buyback program

  • 2 tuck-in acquisitions totaling $4.4M ($3.4M cash + $1M earnout)

  • Buybacks ran >10:1 vs M&A spend (most informed buyer choosing own stock over practice acquisitions)

  • Yellow flag on sub-scale therapy practice valuations in private markets

  • Buyback essentially offsetting RSU dilution, not reducing share count

  • $128.5M unrecognized stock comp over 2.3 years = ~$56M/year future SBC

Balance Sheet

  • $194.8M cash, down $54M from $248.6M (buybacks + RSU tax withholding)

  • $290M term loan at SOFR+3% (~7.3% effective)

  • $100M revolver undrawn, meaningful dry powder

  • Net leverage covenant 4.5x; interest coverage minimum 3.0x; in compliance

  • Goodwill $1.30B vs total assets $2.15B (60% of balance sheet is roll-up legacy)

  • LifeStance trade name = $174M intangible asset, 22.5-year useful life

  • TPG + Summit still own 43.6% combined post-IPO (sponsor overhang remains)

Market Position & Strategy

  • Largest national outpatient mental health platform by clinician count

  • Competition is local, not national (mental health still fragmented at practice level)

  • Acquisition strategy: tuck-ins in new markets for entry, existing markets for density

  • Larger M&A targets sitting at valuations “dislocated from reality”

  • No material M&A in 2026 baseline expectations

  • Organic and productivity-led growth is the working model

The Connective Thesis

  • LifeStance proving scaled outpatient mental health can generate real margins, but only after reaching size where fixed costs stop eating you

  • Two-payor concentration looks risky until you realize it’s a moat at must-have scale

  • Buyback-over-M&A signal suggests sub-scale therapy practices are overpriced in private markets

  • Unresolved 7-year-old internal control weaknesses hint at integration debt these roll-ups carry (warning for anyone underwriting consolidation plays)

  • Silence on virtual/in-person mix is the conspicuous gap; telehealth rate parity is the single biggest reset risk in the category

  • For startups: payor leverage is a step function, not a gradient; until you’re must-have in a market, you’re a price-taker

  • Mental health roll-ups inherit fragmented EHRs, billing, compliance from acquired practices, the integration debt compounds